Table 3 Subgroup Meta-analysis of FPR and RFS
Subgroup | No.of cohorts | No. of patients | Pooled HR (95% CI) | P | Heterogeneity I2 (%) Ph | |
|---|---|---|---|---|---|---|
Altogether | 4 | 1920 | 2.29(1.91,2.76) |  < 0.001 | 35.3 | 0.201 |
Publishing time | ||||||
  < 2021 | 1 | 230 | 1.77(1.04,2.99) | 0.034 | NA | NA |
  ≥ 2021 | 3 | 1690 | 2.32(1.73,3.11) |  < 0.001 | 43.6 | 0.170 |
Sample capacity | ||||||
  < 480 | 2 | 387 | 1.94(1.26,2.99) | 0.002 | 0.0 | 0.534 |
  ≥ 480 | 2 | 1533 | 2.38(1.94,2.92) |  < 0.001 | 71.8 | 0.060 |
Study designed type | ||||||
 Retrospective | 1 | 157 | 2.36(1.12,4.99) | 0.025 | NA | NA |
 Prospective | 3 | 1763 | 2.17(1.59,2.97) |  < 0.001 | 56.8 | 0.099 |
Cancer site | ||||||
 HCC | 1 | 230 | 1.77(1.04,2.99) | 0.034 | NA | NA |
 CRC | 3 | 1690 | 2.32(1.73,3.11) |  < 0.001 | 43.6 | 0.170 |